leadf
logo-loader
viewFSD Pharma
(
CSE:HUGENASDAQ:HUGE
)

FSD Pharma files New Animal Drug Application with FDA for FSD201 to treat gastrointestinal enteropathy in dogs

The proposed design is a randomized and double-blind trial of 200 dogs that will compare FSD201 dosed twice daily to a placebo for the treatment of canine inflammatory bowel disease

FSD Pharma - FSD Pharma Inc files Investigational New Animal Drug Application with US Food and Drug Administration for FSD201 to treat gastrointestinal enteropathy in dogs
FSD Pharma said the primary endpoint will be a validated diarrhea score, evaluated by both the treating veterinarian and the dog owner

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) said it has submitted to the US Food and Drug Administration an Investigational New Animal Drug Application (IND) for the use of FSD201 to treat gastrointestinal enteropathy in dogs. 

The application has been accepted for review, the company added in a statement.

The proposed trial design is a randomized, double-blind, placebo-controlled, crossover, study comparing FSD201 (ultra micronized palmitoylethanolamide, or ultramicronized PEA) dosed twice daily for 30 days to a placebo for the treatment of canine inflammatory bowel disease. 

READ: FSD Pharma in license agreement with Innovet Italia to develop FDA-approved drugs to treat gastrointestinal diseases in dogs and cats

FSD Pharma said the primary endpoint will be a validated diarrhea score, evaluated by both the treating veterinarian and the dog owner. The trial will be conducted at five-10 sites in the US, and will enroll up to 200 dogs.

In other company news, FSD Pharma thanked shareholders for the strong support it has received ahead of its upcoming Annual and Special Meeting of Shareholders.

On May 5, FSD Pharma announced that Institutional Shareholder Services Inc (ISS), a leading independent international corporate governance analysis and proxy advisory firm, had recommended that shareholders vote for all management director nominees and for the elimination of the dual-class share structure at the meeting.

Shareholders are urged to vote immediately to ensure their proxies are received by the proxy voting deadline – no later than 9 am (Toronto time) on May 12. Shareholders with questions or who require assistance voting their shares should contact the company's proxy solicitation agent Gryphon Advisors Inc at 1.833.292.5847 toll-free in North America (1.416.902.5565 by collect call) or by email at inquiries@gryphonadvisors.ca.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: FSD Pharma

Follow
CSE:HUGE

Price: 1.98 CAD

Market Cap: $70.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma 'excited' to acquire pharma group Lucid Psycheceuticals to...

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc (CSE:HUGE) (NASDAQ:HUGE) Interim CEO Anthony Durkacz tells Proactive the group is to buy Canada-based specialty psychedelic pharma group Lucid Psycheceuticals Inc in a stock deal worth around US$9 million (C$11.3 million). Durkacz says the life sciences...

3 weeks, 5 days ago

2 min read